A Comparison of the Skeletal Effects of Goserelin and Danazol in Premenopausal Women with Endometriosis
article
OA: closed
CC0
⤵ 18 in-corpus citations
AI-generated summary
Goserelin treatment caused a small decline in spinal bone density and a greater loss in the proximal femur, while danazol treatment did not impact bone density.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
The skeletal effects of two therapies for endometriosis that produce hypo-oestrogenism in 23 premenopausal women have been studied. Eleven women received goserelin 3.6 mg monthly by subcutaneous implant and 12 women received danazol 600 mg daily, orally, both for 6 months. Goserelin causes a small decline in spinal bone density, but a greater loss of density in the proximal femur. Preliminary results show no evidence that bone loss is reversible after stopping therapy. Danazol treatment is not associated with loss of bone. Prolonged or repeated courses of treatment with goserelin alone could lead to a clinically significant adverse effect on the skeleton.
My notes (saved in your browser only)
Condition tags
MeSH descriptors
Citation neighborhood
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.
Cited by (18)
- Danazol 2022
- The effect of pharmacological cessation and restoration of menstrual cycle on bone metabolism in premenopausal women with endometriosis 2022
- Raloxifene Administration in Women Treated with Long Term Gonadotropin-releasing Hormone Agonist for Severe Endometriosis: Effects on Bone Mineral Density 2016
- Hormone therapy for endometriosis and surgical menopause 2009
- Hormone therapy for endometriosis and surgical menopause 2006
- Long-term effects on bone mineral density and bone metabolism of 6 months’ treatment with gonadotropin-releasing hormone analogues in Japanese women: comparison of buserelin acetate with leuprolide acetate 2005
- Bone metabolism in postmenopausal women who were treated with a gonadotropin-releasing hormone agonist and tibolone 2002
- Long-term use of gonadotropin-releasing hormone analogs and hormone replacement therapy in the management of endometriosis: a randomized trial with a 6-year follow-up 2000
- Low-dose danazol after combined surgical and medical therapy reduces the incidence of pelvic pain in women with moderate and severe endometriosis 1999
- GnRH agonists and add‐back therapy: is there a perfect combination? 1998
- Effectiveness of tibolone on hypoestrogenic symptoms induced by goserelin treatment in patients with endometriosis 1997
- Goserelin 1996
- The impact of bone loss in women with endometriosis 1995
- Goserelin (Zoladex) and the skeleton 1994
- An alternative to hysterectomy? GnRH analogue combined with hormone replacement therapy 1993
- Endometriosis 1993
- GnRH Agonists in the Treatment of Endometriosis 1993
- Goserelin (Zoladex ) depot in the treatment of endometriosis 1992
Source provenance
- europepmc
- last seen: 2026-06-04T01:30:01.192114+00:00
- openalex
- last seen: 2026-06-04T00:00:01.174412+00:00
- pubmed
- last seen: 2026-05-13T22:09:15.954262+00:00
License: CC0
· commercial use OK